Novo Nordisk A/S Sponsored ADR (NVO)
Italy set to speed through $2.3 billion Novo Nordisk investment
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.
Novo Nordisk's Sell-Off Has Gone Too Far
Novo Nordisk's recent sell-off is overdone; current fears around pricing and CagriSema are temporary, creating a compelling buying opportunity. The company's fundamentals remain strong, with robust sales growth in Ozempic and Wegovy, and a promising pipeline including oral semaglutide and CagriSema. Regulatory and commercial initiatives should drive patients back to branded GLP-1s, supporting a rebound in sales and earnings through 2025-2026.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) reached $69.82 at the closing of the latest trading day, reflecting a +1.16% change compared to its last close.
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters.
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks struggled to raise capital in a higher-for-longer interest rate environment.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
